

REMARKS

Status of the Claims

Claims 1-33, 35, and 42-46 are pending in the present application. Claim 6 has been cancelled without prejudice to or disclaimer of the subject matter contained therein. Claims 1, 5, 7, and 30 have been amended to recite that R¹ can be C₁-C₆ alkoxy. This amendment is supported by the originally-filed claims and specification including, for example, original claim 6. Applicants reserve the right to file continuing applications directed to the cancelled subject matter. No new matter is added by way of amendment.

Conclusion

Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

Kathryn L. Coulter

Kathryn L. Coulter
Attorney for Applicant
Registration No. 45,889

Date: 7/1/2008

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1467

Facsimile: (919) 483-7988